A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of Rebiotix RBX2660 (microbiota suspension) for the Prevention of Recurrent Clostridium difficile Infection
Primary Objective
Primary Objective: To confirm the efficacy of RBX2660 as compared to a Placebo in preventing recurrent episodes of CDI through 8 weeks. Secondary Objective: To evaluate the sustained clinical response rate of RBX2660 as compared to Placebo after blinded treatment.
Details
Age
Adult
Type of Study
Treatment
Scope
National
Locations
University of Colorado Hospital
Principal Investigator
Shelby Sullivan, MD
Study ID
Protocol Number: 18-1344
More information available at ClinicalTrials.gov: NCT03244644
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers